Type‐1 plasminogen activator inhibitor in human breast carcinomas

International Journal of Cancer

Volumn 50, Issue 2, 1992, Pages 208-214

  Reilly, David ^a,b   Christensen, Use ^c   Duch, Mogens ^a   Nolan, Naimh ^b   Duffy, Michael J ^b   Andreasen, Peter A ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA; UROKINASE;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANIMAL; BASE SEQUENCE; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; MOLECULAR SEQUENCE DATA; PLASMINOGEN INACTIVATORS; RABBITS; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T;

EID: 0026500518     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910500209     Document Type: Article

References (36)

1. Plasminogen‐activator inhibitors: hormonally regulated serpins
2. Plasminogen‐activator inhibitor from human fibrosarcoma cells binds urokinase‐type plasminogen activator, but not its pro‐enzyme
3. Plasminogen‐activator inhibitor type‐1 biosynthesis and mRNA are increased by dexamethasone in human fibrosarcoma cells
4. Universal immunoperoxidase staining protocol to optimize the use of polyclonal and monoclonal antibodies
5. Detection of the plasmin system in human mammary pathology using immunofluorescence
6. Accessibility of receptor‐bound urokinase to type‐1 plasminogen‐activator inhibitor
7. Receptor‐mediated inlcrnalization and degradation of urokinase is caused by its specific inhibitor PAI‐1
8. Plasminogen activators, tissue degradation and cancer
9. Plasminogen activators and cancer
10. Urokinase‐plasminogen activator, a new and independent prognostic marker in breast cancer
11. The receptor for urokinase‐type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes
12. Plasminogen‐activator inhibitor types 1 and 2 in human trophoblasts. PAI‐1 is an immunocytochemical marker of invading trophoblasts
13. Urokinase‐type plasminogen‐activator (u‐PA) antigen is a predictor of early relapse in breast cancer
14. Lysosomal degradation of receptor‐bound urokinase‐type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells
15. The simultaneous extraction of high‐molecular‐weight DNA and of RNA from solid tumors
16. Plasminogen activator inhibitor type 1 in Lewis lung carcinoma
17. First‐strand cDNA synthesis primed with oligo(dT)
18. Protein inhibitors of proteinases
19. Tumor invasion and metastasis. Role of the extracellular matrix. Rhoads Memorial Lecture
20. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation
21. Metastatic potential correlates with enzymatic degradation of basement membrane collagen
22. Structure of the human plasminogen‐activator inhibitor 1 gene: non‐random distribution of introns
23. Plasminogen activator inhibitor type‐1: cell‐specific and differentiation‐induced expression and regulation in human cell lines, as evaluated by enzyme‐linked immunosorbent assay
24. Monoclonal antibodies to human 54,000‐molecular‐weight plasminogen‐activator inhibitor from fibrosar‐coma cells. Inhibitor neutralization and one‐step affinity purification
25. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family
26. Identification of a serpin‐erizyme complex receptor on human hepatoma cells and human monocytes
27. 1‐proteinase inhibitor deficiency
28. The pathogenesis of cancer metastasis
29. Cell‐associated plasminogen activation: regulation and physiological functions
30. Increase of urokinase‐type pjasminogen activator gene expression in human lung and breast carcinomas
31. A better cell line for making hybridomas secreting specific antibodies
32. Immunocytochemical localization of urokinase‐type plasminogen activator in Lewis lung carcinoma
33. Plasminogen activators and tumor invasion
34. Characterization of plasminogen activators from normal breast and colon and from breast and colon carcinomas
35. Functional and morphological expressions of trophoblast